News
DCTH
4.850
-4.72%
-0.240
Netflix To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Barclays cut the price target for Prologis, Inc. And increased Netflix's price target from $615 to $725 on Tuesday. Berry Global Group's stock price target slashed from $75 to $68. Intuit shares gained 0.2% to close at $640.05. Wells Fargo & Company's stock was downgraded to Market Perform.
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Zevra Therapeutics (ZVRA) and Corcept Therapeutics (CORT)
3 analysts have maintained Buy ratings on Delcath Systems, Zevra Therapeutics and Corcept Therapeutic. The Healthcare sector is expected to be a hot area for insiders to make moves in the coming months. The 3 stocks have a combined market value of more than $1.5 billion.
TipRanks · 1d ago
Delcath Systems Price Target Raised to $20.00/Share From $18.00 by HC Wainwright & Co.
Dow Jones · 1d ago
Delcath Systems Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $20
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Aerovate Therapeutics (AVTE) and Delcath Systems (DCTH)
TipRanks · 1d ago
Delcath Systems, Inc. Under ESG Spotlight: Navigating New Compliance Challenges and Financial Implications
TipRanks · 1d ago
DCTH Stock Earnings: Delcath Systems Beats EPS, Misses Revenue for Q4 2023
Delcath Systems reported earnings per share of -48 cents. The company reported revenue of $539,000. This was 0.19% worse than the analyst estimate for the company to report revenue of -50 cents. Delcath systems is down 7.7% in the last week.
Investorplace · 1d ago
Delcath Sys: Annual report
Press release · 1d ago
Delcath Systems Inc reports results for the quarter ended in December - Earnings Summary
Delcath Systems Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 48 cents per share. Revenue fell 33.5% to $539.00 thousand from a year ago. Delcath systems Inc shares had risen by 12.0% this quarter.
Reuters · 2d ago
*Delcath Systems Boosts 2024 Treatment Site Activation Guidance to 20 Sites >DCTH
Dow Jones · 2d ago
*Delcath Systems 4Q Loss $11.1M >DCTH
Dow Jones · 2d ago
*Delcath Systems 4Q Rev $539,000 >DCTH
Dow Jones · 2d ago
Delcath Systems GAAP EPS of -$0.48, revenue of $0.54M
Seeking Alpha · 2d ago
Delcath Systems Q4 GAAP EPS $(0.48) Beats $(0.51) Estimate, Sales $539.00K Miss $540.00K Estimate
Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $0.48 per share. The company reported quarterly sales of $539.00 thousand which missed the analyst consensus estimate by 15.65 percent. Delcath systems beat the quarterly sales estimate by 5.88 percent.
Benzinga · 2d ago
*Delcath Systems 4Q Loss/Shr 48c >DCTH
Dow Jones · 2d ago
Press Release: Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update. The company is focused on the treatment of primary and metastatic cancers of the liver. Delcath announces first commercial use of HEPZATO KIT for metastatic uveal melanoma. Updated 2024 treatment site activation guidance from 15 active sites to 20 sites.
Dow Jones · 2d ago
Press Release: Delcath Systems Reports Fourth -2-
DELCATH SYSTEMS, INC. Has $1.2 billion in cash and cash equivalents. The company has more than $3 billion in total assets. The company reported its financial results for the quarter ended December 31, 2013. The firm has a total of $3.3 billion and $1 billion in assets.
Dow Jones · 2d ago
Earnings Scheduled For March 26, 2024
Bluebird bio is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. AIM ImmunoTech is estimated to report earnings for its fourth quarter. Elbit Systems is projected to report. Quarterly earnings at $1.38 per share.
Benzinga · 2d ago
Pre-Market Earnings Report for March 26, 2024 : ABOS, BLRX, CGTX, DCTH, DOYU, ESLT, GDS, LLAP, MKC, SNX
NASDAQ · 2d ago
More
Webull provides a variety of real-time DCTH stock news. You can receive the latest news about Delcath Sys through multiple platforms. This information may help you make smarter investment decisions.
About DCTH
Delcath Systems, Inc. is an interventional oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company’s proprietary products, HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO Kit is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it has been used in the conduct of percutaneous hepatic perfusion procedures at medical centers to treat a range of cancers of the liver.